maraciclatide
Phase 3- Indications
- Rheumatoid arthritis, Psoriatic arthritis, Endometriosis
Company intelligence / Profile preview
Serac Healthcare develops molecular imaging agents to improve diagnosis and monitoring of diseases characterized by abnormal angiogenesis. Its lead product, the radiopharmaceutical tracer "99mTc-maraciclatide," targets αvβ3 integrin to visualize inflammation non-invasively. The company has completed multiple early-phase studies showing correlation with established diagnostic methods. It has received FDA Fast Track designation for endometriosis imaging and plans to initiate pivotal Phase III trials in both endometriosis and inflammatory arthritis soon. The technology aims to enable whole-body imaging within minutes, supporting personalized medicine approaches.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Serac Healthcare.